View more on these topics

Framlington goes for biotech

Framlington Unit Management is taking the pulse of the specialist market with its new biotech fund.

Biotech is a unit trust aimed at experienced investors who are looking for a high-risk product for their portfolios.

The fund will invest in a portfolio of 80 biotechnology companies, the majority of which are based in the US and the others dotted around the globe. The companies chosen will be well-established and involved in the research and development of biotechnology products only.

All the companies chosen will either be involved in late stage technical trials or will be applying for registration of new drugs and treatments for serious diseases such as HIV and cancer. In order to minimise the risk, companies with more than one upcoming product will be picked.

The fund will be managed by Antony Milford who has been in charge of the Framlington health fund since 1989 and he will be advised by a panel of healthcare experts.

Framlington has introduced the fund at a time when prices are low and it could pick up some good value stocks. However, investors should look at this fund with an eye on the long-term as, as over the short-term it could prove to be too volatile for most. But one attraction of the biotechnology market is that in a world with an aging population, the need for medical advancement and drugs will increase in years to come.

According to Standard & Poor’s the Framlington health fund is ranked 3 out of 23 funds, based on £1,000 invested on a bid-to-bid basis with gross income reinvested over three years to October 22, 2001.


R&SAIFS feels agressive with new fund

Royal & SunAlliance International Financial Services’ (R&SAIFS) new aggressive managed fund is introduced in co-operation with Collins Stewart Asset Management, who will be dealing with the management of the fund.Aggressive managed is an offshore life insurance fund of funds and potential investors have been identified as experienced investors who are looking to add a high-risk […]


Are you more likely to recommend a product if it is accredited with the ABI&#39s Raising Standards quality mark?“No. Products have to be assessed on their own merits whether or not it carries such a mark.”Paul Rayner,Rayner Woolner“No, I&#39d look at each product and recommend it or not on its individual merits.”Martin Sell,MR Sell Financial […]

Premier Fund Managers – Premier x-cel Portfolio

Tuesday, October 23, 2001.Aim: Income and growth by investing in UK and overseas equities,unit trusts and investment trusts. Minimum investment: £150,000.Investment split: Choice of UK and overseas equities, unittrusts and investment trusts.Income facility: Monthly, quarterly, half-yearly, annually.Charges: Annual 0.75-1.25 per cent.Commission: Initial up to 3 per cent, renewal 0.5 per cent.Tel: 01483 306090.

Portfolio is set to offer blue-chip protection

Legal & General is introducing a new protected portfolio which offers investors growth while giving some protection on their capital.The protected portfolio is available for investments from October 22 until November 30. It invests in 30 stocks selected from the top 200 UK companies and has a five-year term with capital security at the fifth […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment


    Why register with Money Marketing ?

    Providing trusted insight for professional advisers.  Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm